Miguel Abal Posada

Title: Innovations in Endometrial Cancer Detection by Miguel Abal Posada

Introduction

Miguel Abal Posada is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of medical diagnostics, particularly in the detection of endometrial cancer. His innovative work has the potential to improve early detection and treatment outcomes for patients.

Latest Patents

Miguel Abal Posada holds a patent for "Markers for endometrial cancer." This invention is based on the discovery that specific biomarkers, including ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN, are differentially expressed in samples from patients with endometrial cancer compared to control samples. These biomarkers demonstrate excellent sensitivity and specificity, making them valuable for detecting the disease. Furthermore, the correlation between the expression levels of these biomarkers in tumor tissue and uterine fluid samples enhances their robustness in clinical applications.

Career Highlights

Miguel Abal Posada is associated with Geadic Biotec, a company focused on biotechnological innovations. His work at Geadic Biotec has allowed him to collaborate with other experts in the field, contributing to advancements in cancer diagnostics.

Collaborations

Miguel has worked alongside notable colleagues, including Andreas Doll and Antonio Gil Moreno. Their combined expertise has fostered a collaborative environment that promotes innovation in medical research.

Conclusion

Miguel Abal Posada's contributions to the detection of endometrial cancer through innovative biomarkers represent a significant advancement in medical diagnostics. His work has the potential to enhance early detection and improve patient outcomes in the fight against cancer.